Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 4′-deoxydoxorubicin  (1)
  • Adjuvante, perioperative Chemotherapie  (1)
  • Castleman's disease  (1)
  • DLCL  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Hodgkin's and Castleman's disease in a patient with systemic mastocytosis (1999)
    Springer
    Annals of hematology 78 (1999), S. 97-100 
    Details
    ISSN: 1432-0584
    Keywords: Key words Systemic mastocytosis ; Hodgkin's disease ; Castleman's disease ; Chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  Systemic mastocytosis is a rare condition characterized clinically by the local consequences of vasoactive peptides released from infiltrating mast cells in the reticuloendothelial tissues. Mast cells originate from the pluripotent bone marrow stem cells; it is therefore not surprising that myeloproliferative and myelodysplastic disorders commonly coexist or terminate the clinical phase of mastocytosis. We report here, to our knowledge, the first case of Hodgkin's and Castleman's disease occurring in a patient with co-existent systemic mastocytosis, which remained unchanged after combination chemotherapy for Hodgkin's disease.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002770050482
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma (1999)
    Springer
    Annals of oncology 10 (1999), S. 1433-1440 
    Details
    ISSN: 1569-8041
    Keywords: combined-modality treatment ; DLCL ; PGL ; stage-modified IPI
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: The definition of prognostic parameters in early stages of gastric lymphoma is still controversial. The aim of this retrospective analysis was to assess the value of the stage-modified international prognostic index (IPI) in predicting the outcome of a large, consecutive series of patients with PGL of diffuse large B-cell histology (DLCL). Patients and methods: Three hundred twelve consecutive, newly-diagnosed, patients with localized PGL (stages I–IIE according to the ‘Lugano staging system for GI lymphomas’) referred from April 1972 to December 1997 to eight Italian and one Swiss centers were reviewed and their outcomes updated to June 1998. One hundred three patients were treated with single-modality therapy, while two hundred four received combined-modality treatment, most of which included surgery and short-term chemotherapy. Results: After a median follow-up of 66 months (range 0.6–300 months), 195 (64%) were alive in first continuous complete remission (CCR). The five-year estimates of overall survival (OS) and event-free survival (EFS) were 75% and 67%, respectively. OS and EFS varied according to IPI, from, respectively, 90% and 82% for patients with 0–1 risk factors, to 40% and 35% for patients with ≥3 risk factors (P = 0.00001). Cox regression analysis showed that IPI was the strongest predictor of survival. Conclusions: This study shows that stage-modified IPI is an effective predictive model in patients with primary DLCL of the stomach, enabling identification of patients with significantly different outcomes.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008351427601
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    263. Adjuvante portale Chemotherapie bei colorectalen Carcinomen, eine multizenterstudie der schweizerischen arbeitsgemeinschaft für klinische krebsforschung (SAKK) (1987)
    Springer
    Langenbeck's archives of surgery 372 (1987), S. 889-889 
    Details
    ISSN: 1435-2451
    Keywords: Adenocarcinoma of the colon and rectum ; Adjuvant perioperative liver infusion ; Liver metastases ; Colorectales Carcinom ; Adjuvante, perioperative Chemotherapie ; Lebermetastasen
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Untersucht wird beim colorectalen Carcinom die Wirkung einer perioperativen portalen Leberperfusion mit 5-Fluorouracil und Mitomycin C. Zur Zeit sind 409 Patienten auswertbar, 202 im Kontroll- und 207 im Behandlungsarm. Die bisherigen Resultate (März 87), bei einer Beobachtungszeit von 35 Monaten, zeigen im Behandlungsarm eine deutlich geringere Tendenz für Lebermetastasen (10,4% vs 6,3%), besonders auch in den Untergruppen (Colon 11,5% vs 6,8% und Dukes' C: 22,2% vs 6,9%). Entsprechend ist auch der Carcinom-Tod seltener (14,4% vs 12,1%; 15,8% vs 8,5% und 25,4% vs 15,5%). Die Beobachtungszeit ist für eine statistische Analyse noch zu kurz.
    Notes: Summary The efficacy of adjuvant, perioperative portal liver infusion with 5-fluorouracil and mitomycin C was investigated (409 patients, 202 control subjects, 207 treated). Liver metastases were detected in 10.4% of the untreated vs 6.3% of the treated patients. The median follow-up was 35 months. For the colon subgroups (excluding the rectum) and Dukes' C tumors alone, the corresponding results were as follows: 11.5% vs 6.8% and 22.2% vs 6.9%, respectively. Death from progressive cancer disease occurred in 14.4% vs 12.1% of all patients: 15.8% vs 8.5% (colon) and 25.4% vs 15.5% (Dukes' C), respectively. The follow-up time is too short for statistical analysis, however.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01298047
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Phase I trial of 4′-deoxydoxorubicin given weekly (1984)
    Springer
    Investigational new drugs 2 (1984), S. 369-374 
    Details
    ISSN: 1573-0646
    Keywords: Phase I trial ; 4′-deoxydoxorubicin ; esorubicin
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Twenty-six patients with various solid tumors entered a Phase I trial with 4′ -Deoxydoxorubicin (Esorubicin, IMI-58), a new doxorubicin analogue. The drug was administered weekly i.v. for 3–4 weeks. Leukopenia proved to be dose limiting. The maximum tolerated dose (MTD) was reached at 20 mg/m2 weekly for 3 weeks. For Phase II trials, a weekly dose of 15 and 17.5 mg/m2 can be proposed for poor and good risk patients respectively. Non-hematologic toxicity was minimal. Phase II trials with this new anthracycline are warranted.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00171587
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...